Cofactor closes the precision medicine gap with predictive diagnostics
Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).
Founder
Dr. Dave Messina has over 25 years of experience in healthcare and has been leading healthcare investments at Pioneer Fund since 2019. He has led 100+ deals including top portfolio companies like Gilgamesh ($1B exit to Abbvie) and Assort Health ($500M+ valuation). Previously he founded the RNA and machine learning company Cofactor Genomics (YC S15) and led it to national Medicare reimbursement. Dr. Messina also worked on the Human Genome Project.
